the angiogenesis foundation
angiogenesis foundation: 2010 tedtalk update: dr. william li at tedxmanhattan - youtube
purchase angiogenesis - related books directly through amazon. by clicking through the links below, a portion of your order goes to the angiogenesis foundation
for @ drwilliamli & dr. vincent li' s great work at the angiogenesis foundation. @ u2
the angiogenesis foundation presents its expert perspectives in authoritative reviews published in leading peer - reviewed medical journals and in major textbooks .
the other charities she supports include the american family children’s hospital, leukemia and lymphoma society, st. jude children’s research hospital, the university of wisconsin foundation, and the little star foundation .
shawna cornelius li has been involved with the angiogenesis foundation since its inception in 1994, and became a board member in 1997. as its executive director from 1994 - 1999, shawna wrote the foundation’s initial application for– and secured– its federal tax - exempt status, and developed all scientific and communications materials during the foundation’s start - up phase. she also coordinated the foundation’s debut at the nato institute for advanced studies conference on angiogenesis, held in europe in june 1995 .
the angiogenesis foundation seeks to improve patients outcomes in disease treatment and prevention on a global level, by democratizing the transfer and use of expert medical knowledge .
since navy' s success, the angiogenesis foundation is working to help pets and their owners overcome cancer on a case - by - case basis. the foundation continues to receive telephone calls from pet owners and veterinarians who have heard about navy .
haber persuaded researchers at the foundation to design a treatment for navy. no one thought the pup had a prayer .
the cleveland metroparks zoo and the angiogenesis foundation hope that exotic animals will be among those that benefit from anti - angiogenic therapies, even if the navy protocol does not turn out to be the answer .
u2’s bono gives shout out to dr. william li and dr. vincent li at the u2 show in boston. u2 guitarist the edge sits on the angiogenesis foundation’s board. l ...
haber, 24, knew about this form of experimental cancer treatment because she had worked as a research fellow at the angiogenesis foundation, a non - profit organization based in cambridge, mass. created in 1994, the foundation promotes research on angiogenic treatments by teaming drugmakers with scientists .
sir roger moore (1927 - 2017) was a special advisor and friend to the angiogenesis foundation, starring in an advocacy video and working to raise awareness for disease - related vision loss .
dr. vincent w. li is the chief operating officer and scientific director of the angiogenesis foundation. he has been involved in the field of angiogenesis since 1998, and has been on the board since its inception in 1994. dr. li conducted his bachelor’s thesis with harvard professor howard green, a pioneer of epidermal and fibroblast biology, and performed his doctoral dissertation on growth factors and tumor angiogenesis as a howard hughes medical institute fellow in the research laboratory of angiogenesis pioneer dr. judah folkman .
william w. li is chief executive officer, president, medical director, and co - founder of the angiogenesis foundation. will trained in the lab of dr. judah folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 30 years. under will’s leadership, the foundation has developed a unique social enterprise model based on value creating collaborations with leading medical academic centers, biopharmaceutical and medical device companies, and government agencies, including the national institutes of health, food and drug administration, and centers for medicare and medicaid services .
angiogenesis, the growth of new capillary blood vessels in the body, is an important natural process used for healing and reproduction. the body controls angiogenesis by producing a precise balance of growth and inhibitory factors in healthy tissues .
anti - angiogenic drugs are showing a great deal of promise in that respect. so far, researchers have been able to
freeze cancer in its tracks
in some cases using the drugs, says william li, president of the angiogenesis foundation .
developed and published by the angiogenesis foundation, targeting tumor angiogenesis is a peer - reviewed, professional publication designed to give physicians and nurses state - of - the - art information and expert perspectives on late - breaking clinical data and new concepts on antiangiogenic cancer treatment and clinical trials. its unique format incorporates clear, concise text and infographics. striking, digital 3 - d illustrations highlight the steps of tumor angiogenesis at the organ, cell, and molecular levels .
dimitris tsakayannis, m. d. , ph. d. is a founder of the angiogenesis foundation, and has served on its board of directors. dr. tsakayannis has conducted research on angiogenesis in cancer with dr. judah folkman and has made significant contributions in advancing the field angiogenesis - based therapies in wound healing. dr. tsakayannis is a specialist in the open and laparoscopic surgical treatment or intraabdominal malignancies, and practices in athens, greece .
angiogenesis - based medicine — restoring the body’s natural control of angiogenesis — is a wide - ranging approach to fighting disease. by using new medical treatments that either inhibit or stimulate angiogenesis, doctors are prolonging the lives of cancer patients, preventing limb amputations, reversing vision loss, and improving general health .
tumor angiogenesis as a target for dietary cancer prevention. j oncol 2012. read this article .
the angiogenesis foundation’s philosophy is that it is critical to engage and educate physicians in order for patients to fully benefit from the promise of new angiogenesis treatments. based on our patient advocacy work, we know that an informed patient needs a knowledgeable physician in order to receive the best care. each physician we educate transfers our impact to thousands of patients we would otherwise not be able to reach directly, a phenomenon we call the “multiplier effect” .
over the past three weeks, the foundation has helped administer the navy protocol to a dozen dogs. there have been changes in the dogs' tumors, but li says it is still too early to tell whether the results will be as dramatic as navy' s .
after completing his medical residency in clinical pathology and clinical preventive medicine at duke university medical center, he went on to become the chief of the division of epidemiology for the american health foundation in new york city. while at the american health foundation dr. harris worked closely with dr. ernst l. wynder and initiated early idemiologic studies of nonsteroidal anti - inflammatory drugs (nsaids) in the prevention of breast cancer and other malignancies .
the angiogenesis foundation convenes national and international expert panels comprised of multiple stakeholders (scientists, investigators, association leaders, technology assessors, government representatives, payers, and health policy experts) to roadmap issues, challenges, and key solutions to improve patient outcomes, with resulting white paper recommendations .
hyperbaric oxygen (hbo) promotes angiogenesis and wound healing by increasing vegf expression and recruiting endothelial progenitor cells .
dr. giannoula klement, an internationally recognized expert on tumor angiogenesis and antiangiogenic therapy, worked with judah folkman elucidating the role of platelets in angiogenesis and their possible role as biomarkers in the early detection of cancer and tumor recurrence. because the majority of angiogenesis regulatory factors appear to be sequestered in platelets, which possess the ability to selectively accumulate these factors in patients with cancer, they have the potential to detect tumor growth before it is clinically apparent .
if you see an elevation in an animal' s angiogenic growth factors, that' s a red flag to look for a tumor ,
says chris bonar, associate veterinarian at the cleveland metroparks zoo. bonar collaborated with the angiogenesis foundation and antony moore, head of the harrington oncology program at the tufts university school of veterinary medicine, to design and monitor navy' s treatment .
factors controlling ocular angiogenesis. american journal of ophthalmology 1997; 124: 521 - 29. read this article .
his research also includes identifying biomarkers for the evaluation of novel targeted therapies, mechanisms of tumor angiogenesis and angiogenesis inhibitors, and looking at parallels between wound angiogenesis and tumor angiogenesis. dr. hurwitz has a particular interest in gastrointestinal cancer and is co - leader of the duke gastrointestinal oncology program. as a recognized gi cancer expert, dr. hurwitz was the principal investigator of the pivotal phase iii trial of the antiangiogenic agent bevacizumab (avastin), in combination with ifl, for metastatic colorectal cancer (mcrc). this seminal trial, published in the new england journal of medicine in june 2004, led to the approval of avastin for mcrc and validated the antiangiogenic approach for cancer therapy .
navy' s treatment was designed using what researchers call a
multi - targeted
approach, meaning that each drug targets a different angiogenesis growth factor. these growth factors are like switches that
turn on
angiogenesis, signaling the body to grow new blood vessels that feed the tumors .
how is angiogenesis important for health? angiogenesis, the growth of new capillary blood vessels in the body, is an important natural process in the body used for healing and reproduction. the body controls angiogenesis by producing a precise balance of growth and inhibitory factors in healthy tissues. when this balance is disturbed, the result is either too much or too little angiogenesis. abnormal blood vessel growth, either excessive or insufficient, is now recognized as a
common denominator
underlying many deadly and debilitating conditions, including cancer, skin diseases, age - related blindness, diabetic ulcers, cardiovascular disease, stroke, and many others. the list of diseases that have angiogenesis as an underlying mechanism grows longer every year. learn more at angio. org! show less
dr. richard beliveau is director of the laboratory of molecular medicine at service de neurochirurgie, hopital, notre - dame (chum), and an expert on tumor angiogenesis. in his position, dr. beliveau oversees a number of important angiogenesis - based research projects involving the regulation of vegf - dependent signaling pathways, contribution of bone marrow - derived cells in tumor angiogenesis, and the identification of new molecular targets and biomarkers, among others .
according to a morris animal foundation survey, the no. 1 concern of american pet owners today is cancer. domestic animals are living longer because of improved health care and nutrition, so they naturally develop more cancers .
using the navy protocol, doctors
sent in three smart bombs
to attack the growth factors, li says. if the growth factors can' t send signals to the rest of the body, angiogenesis can' t take place. then researchers can
pull the rug out from under the cancer ,
li says .
alzheimer’s disease and angiogenesis. lancet 2003 feb 15; 361 (9357): 605 - 8. read this article .
christopher j. bonar, v. m. d. has served on the angiogenesis foundation’s board of directors since its inception in 1994. he is a founding member and current chairman of the board. dr. bonar is co - founder and president of the cleveland aquarium. he holds the position of adjunct associate professor in the department of veterinary preventive medicine, college of veterinary medicine, the ohio state university, and serves as both consulting veterinarian for the cleveland botanical garden and as consulting veterinarian and research associate for the cleveland museum of natural history .
gerald gehr, m. d. has been involved with the angiogenesis foundation since 1995, first as a clinical advisor, and then as a board member since 2002. he is chief of hematology oncology at the department of veterans affairs medical center in manchester, new hampshire, has full - time clinical appointments at several new hampshire hospitals, and serves as medical director of the manchester vna hospice program .
over the course of our organization’s history, the foundation has been involved in many diverse, strategic programs tailored to the swiftly changing nature of scientific and medical research, the educational needs of the health care community, the evolving industry and regulatory and payer environments, and the impact of health care economics of actual health care itself. our present programs are centered around: outreach, education, and research .
although the navy protocol appears promising to cancer - ridden pets, li says, the foundation is not pushing the cocktail as the only way to treat canine cancers. other anti - angiogenic drugs, such as abbott laboratories' abt - 510 and abt - 526, also are being used in pet clinical trials .
a small molecule inhibitor of mtor (mammalian target of rapamycin), part of the pi3 kinase / akt pathway involved in tumor cell proliferation and angiogenesis .
his group is focusing on angiogenesis in tumor growth, inflammation, fibrosis, and wound healing as well as on clinical anatomy .
tumor angiogenesis as a target for dietary cancer prevention. j oncol 2011; 2012: 1 - 23. read this article .
as president, will has testified and presented before congressional and other government panels on the impact of angiogenesis in healthcare, and lectures around the world on angiogenesis - related topics in front of clinical, government, and industrial audiences. he is actively engaged in global efforts to advance the applications of angiogenesis - based therapeutics across diverse medical fields, including oncology / hematology, cardiology, ophthalmology, vascular surgery, dermatology, wound care, and regenerative medicine. he has been published in science, the new england journal of medicine, the lancet, nature reviews and other leading peer - reviewed medical journals. will’s ted talk on angiogenesis has received more than 11 million views .
his current philanthropic focus is with the angiogenesis foundation, bayes impact and the onehope foundation, and random acts of kindness. pankaj is also an advocate for every mother counts, virgin unite and witness. previously, he proudly served on the board of directors for brac usa and girls, inc and supported music rising. brac usa aims to end extreme poverty in africa and asia through innovative, entrepreneurial development programs. brac is the largest non - profit social enterprise in the developing world and focuses on microfinance, health, education, and social justice. girls, inc. , is a national non - profit youth organization dedicated to inspiring all girls to be strong, smart and bold .
the edge, born david howell evans, has served on the angiogenesis foundation’s board of directors since 2007. he is a guitarist with the irish rock band u2, and is commonly described as one of the most influential guitarists of his generation. one of the principle songwriters of u2, the edge has also written extensively for other projects, including movie scores (captive, gangs of new york, golden eye), for animated series (the batman tv series), and for the stage (a clockwork orange by the royal shakespeare company 1990), and often works in collaboration with u2′s lead singer, bono .
as acting chief strategy officer of the angiogenesis foundation, eric lowitt works with the executive team to ignite paradigm - shifting innovations in health promotion and disease prevention to improve health outcomes for people around the world. over the course of his career, eric has advised fortune 500 ceos, senior public officials, and leaders of nongovernmental organizations in health, strategy, collaboration, and sustainability. he has worked for nearly two decades with accenture, fidelity investments, and deloitte consulting .
dr. albini’s extensive honors include the 2015 special recognition award by the european union women inventors and innovators network international (euwiin), as well as the 2014 donne che ce l’hanno fatta (women who made it) award by the provincial council of brescia. as a champion for women in the field of science, dr. albini has fostered the careers of other female investigators, contributed to wicr activities, and published for the veronesi foundation .
cancer prevention by targeting angiogenesis. nat rev clin oncol 2012 sep; 9 (9): 498 - 509. read this article .
diana develops innovative strategies for advancing health initiatives surrounding the prevention of non - communicable diseases, such as cancer, vision loss, and chronic wounds. she works with leaders in the healthcare and pharmaceutical industry, ngos, patient advocacy, and medical associations to align interests and create high impact collaborations supporting the angiogenesis foundation’s mission. she has served as a delegate at the clinton global initiative, at patient - centered outcomes research institute programs, and at strategic advocacy summits across europe and north america .
dan rutz has served on the board of directors of the angiogenesis foundation since 2002. he is a risk communications specialist and public health analyst for the centers for disease control and prevention (cdc) in atlanta, ga. , where he is engaged in planning (preparation and response) for public health emergencies, including emerging infectious diseases and bio - terrorism threats. dan also works on the world health organization (who) initiative to establish, develop, and test an international standard for outbreak risk communication .
negative pressure wound therapy (npwt) such as the vacuum assisted closure (v. a. c .) system induces angiogenesis through tissue microdeformations and mechanochemical coupling and signal transduction .
the role of therapeutic angiogenesis in tissue repair and regeneration. adv skin wound care. 2005 nov - dec; 18 (9): 491 - 500. read this article .
therapeutic angiogenesis, in contrast, stimulates angiogenesis where it is required but is lacking. this technique is used to replenish the blood supply to chronic wounds to speed healing, and it prevents unnecessary amputations. new research suggests this approach can also be used to save limbs afflicted with poor circulation, and even oxygen - starved hearts. therapeutic angiogenesis may even help to regenerate damaged or lost tissues in ways that were previously considered impossible, such as with nerves and brain tissue .
louis hook has served on the board of directors of the angiogenesis foundation since 1996. he is currently president of lch technology partners, llc, which provides it and technology management consulting services to public, private and non - profit organizations. he has 19 years experience in communications technology and systems management, and had his own firm, compton. com. partners, llc, which provided communication technology consulting and project management services to public entities .
in addition, at least two other approved angiogenic agents may indirectly inhibit angiogenesis through mechanisms that are not completely understood. finally, in the field of dermatology, there are several agents used for neoplasms of the skin .
in such conditions, the therapeutic goal is to stimulate angiogenesis to improve perfusion, deliver survival factors to sites of tissue repair, mobilize regenerative stem cell populations, and ultimately, restore form and function to the tissue .
scott participates in a wide variety of charitable events, beginning with his own foundation, the scott hamilton c. a. r. e. s. initiative (cancer alliance for research, education and survivorship) at the cleveland clinic taussig center in cleveland, ohio, and provision healthcare foundation in knoxville, tennessee. cares includes offshoots, the fourth angel network and his web site urltoken and radcare. org. he is a tireless supporter of target house at st. jude children’s hospital in memphis, tennessee and livebeyond and best buddies, both of nashville, tennessee. he also serves on the board of directors for monroe carrell’s vanderbilt children’s hospital, special olympics international and provision healthcare foundation. when not commentating, speaking or supporting his favorite charities, scott can be found on the golf course and enjoys spending time with his wife and two sons outside nashville, tennessee .
tumor angiogenesis: molecular pathology, therapeutic targeting and imaging. academic radiology 2000; 7 (10): 800 - 811. read this article .
dr. moritz a. konerding is professor of anatomy at the institute of anatomy at johannes gutenberg university, mainz, germany. one of the early pioneers of angiogenesis research, dr. konerding leads a group focusing on angiogenesis in inflammation, wound healing, and tumor growth, as well as on clinical anatomy. he is an expert on microvascular anatomy and patterns of angiogenesis and the effects of antiangiogenic agents in blood vessels in different organ and tissue systems. dr. konerding received his m. d. from the university of essen, where he did his post - doctoral work in human anatomy .
in a nih - project with the harvard medical school, he investigates the adaptive processes involved in lung regeneration und fibrosis with a focus on microvascular anatomy and patterns of angiogenesis. he serves as medical and strategy consultant to the international management consultancy roland berger strategy consultants .
li w, talcott k, zhai a, kruger e, li v. the role of therapeutic angiogenesis in tissue repair and regeneration adv skin wound care 2005; 18: 491 - 500
the angiogenesis foundation takes a unique approach to achieving our mission to help people lead longer, better, and healthier lives. first, we have the expertise and invest the time and resources to deeply understand the complex needs of our multiple stakeholders, patients, doctors, scientists, industry, regulators, payors, policymakers, the financial community. we seek the input of our advisors, external scientific and medical experts, educators, and our networks of physicians, and patient advocates. we then design programs that best align these interests in ways that can measurably help us meet our mission to help improve patients lives through the angiogenesis field. our program philosophy is that patients can achieve increasingly better outcomes when the needs of different groups involved in both developing and delivering treatment are met. through this process, we fund programs that achieve specific well - defined goals .
in addition to his positive mental attitude, he has spent the past 14 years researching cancer treatments and now incorporates natural anti - angiogenesis, ketogenesis, fasting and the use of phycocyanin, found in spirulina, into his daily regime .
clinical trials in coronary angiogenesis: issues, problems, consensus. circulation 2000 sep 12; 102 (11): e73 - 86. read this article .
nicole firestone, m. b. a. has served on the board of directors of the angiogenesis foundation since 2002. she was a former partner with corriente advisors, llc, a hedge fund based in fort worth, texas with over $ 2. 3 billion in net assets under management, as well as a former principal at goff moore strategic partners, l. p. (gmsp), a company formed in 1998 to serve as a primary investment vehicle for richard e. rainwater .
quentin andrews parker has been a board member of the angiogenesis foundation since 1996. quentin has more than 20 years of work and volunteer experience related to the advancement of higher education, as well as social - and healthcare - related causes. her expertise includes annual giving and major gifts as well as strategic planning, board development, and volunteer management. she has worked both on staff and as a consultant with prestigious educational institutions such as radcliffe college and the kennedy school of government at harvard, as well as with national organizations focused on healthcare, social services, and the arts .
folkman, a researcher at children' s hospital at harvard medical school in boston, discovered in the 1970s that angiogenesis — the growth of new blood vessels — plays a significant role in the development of cancer. since his discovery, an entirely new field of cancer research has developed .
he is also actively in the agricultural division of the american chemical society. he is an active professional member of the institute of food technologists, the american chemical society, the american association of cereal chemists, and the american oil chemists’ society .
we have recruited an internationally renowned faculty of leading medical experts to work with us in teaching physicians who practice in the community. through a variety of accredited teaching methods, publications, lectures, symposia, and webcasts, the foundation has educated a network of over 40, 000 physicians about new treatments, ranging from cancer care to wound care .
a fully human monoclonal antibody (igg1) developed for the treatment of solid tumors. it is directed against the vascular endothelial growth factor receptor 2 (vegfr2). by binding to vegfr2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (vegf) to vegfr2. vegfr2 is known to mediate the majority of the downstream effects of vegf in angiogenesis .
endogenous angiogenesis inhibitor; recombinant protein; blocks vegf - induced tyrosine phosphorylation of kdr - flk - 1 in endothelial cells, and down regulates mmp - 2 / 9 .
when this balance is disturbed, the result is either too much or too little angiogenesis. abnormal blood vessel growth, either excessive or insufficient, is now recognized as a “common denominator” underlying many deadly and debilitating conditions, including cancer, skin diseases, age - related blindness, diabetic ulcers, cardiovascular disease, stroke, and many others. the list of diseases that have angiogenesis as an underlying mechanism grows longer every year .
dr. klement trained with another angiogenesis pioneer, dr. robert kerbel, and with him co - authored a number of papers on antiangiogenic therapy for cancer and the mechanisms of tumor escape from these agents. dr. klement received her m. d. from mcmaster university, canada, and did her residency at the hospital for sick children at the university of toronto, canada. she is the author of numerous papers and textbook chapters on tumor angiogenesis, and was the recipient of the tisdall award for excellence in research, general pediatric section in 1994, and the national cancer institute of canada terry fox postgraduate research fellowship from 1997 - 2000 .
doctor of medicine, institute of functional and clinical anatomy, university medical center, johannes gutenberg - university, mainz, germany. dr. maximilian ackermann leads the angiogenesis and vascular imaging group at the institute of functional and clinical anatomy, university medical center of the johannes gutenberg - university mainz in germany .
before joining baxter, she worked for h. j. heinz in business development and prior to that for technomic consultants a specialist in the foodservice industry. andrea holds bachelor’s degrees in hospital dietetics and foods and nutrition from the university of illinois, and a master of business administration degree from the university of michigan. she is currently on the alliance for regenerative medicine board and has previously served on both the university of illinois medical school advisory board and make - a - wish foundation national board .
navy' s treatment began on christmas day 2000. by early march 2001, her veterinary oncologist could not find a trace of cancer .
that' s a remarkable achievement, for the dog to have no side effects and the tumor be gone ,
says judah folkman, the father of angiogenesis .
he is a member of the societa’ italiana di cancerologia, the societa’ italiana di patalogia, the societa’ italiana di immunologia clinica e allergologia, and the american association for cancer research .
multiple roles of cyclooxygenase - 2 in tumor angiogenesis: a target for antiangiogenic therapy. seminars in oncology 2004; 31 (2) suppl7: 2 - 11. read this article .
below is a collection of our most recent white paper publications addressing angiogenesis - based medicine as it relates to metastatic colorectal cancer, wet age - related macular degeneration, and wound care .
later, the bear was euthanized because of an infection unrelated to the tumor. as he did an autopsy, bonar found the beginnings of pancreatic cancer. he believes the anti - angiogenic drugs suppressed the cancer. it would have been in its acute stages had the bear not been on the drugs, he says .
in the u. s. , there are currently thirteen approved anti - cancer therapies with recognized antiangiogenic properties in oncology. these agents, which interrupt critical cell signaling pathways involved in tumor angiogenesis and growth, comprise three primary categories :
for example, cancerous tumors release angiogenic growth factor proteins that stimulate blood vessels to grow into the tumor, providing it with oxygen and nutrients. a key mechanism of antiangiogenic therapy interferes with the process of blood vessel growth to literally starve the tumor of its blood supply. a new class of cancer treatments that block angiogenesis are now approved and available to treat cancers of the colon, kidney, lung, breast, liver, brain, ovaries, and thyroid, as well as multiple myeloma, bone gastrointestinal stromal tumors, soft tissue sarcoma, and sega tumors. some older drugs have been rediscovered to block angiogenesis, as well. these are being used to treat angiogenesis - dependent conditions, such as hemangiomas, colon polyps, and precancerous skin lesions .
using angiogenesis in chronic wound care with becaplermin and oxidized regenerated cellulose / collagen. nurs clin north am. 2007 sep; 42 (3): 457 - 65. read this article .
in the 1980s, dr. losordo was a research / interventional cardiology fellow at st. elizabeth’s hospital, boston, where he worked with dr. jeffrey isner, a physician who pioneered clinical applications of angiogenesis for pad and ischemic heart disease. he has served as principal investigator on numerous clinical studies of therapeutic angiogenesis, with a particular emphasis on using gene therapy to stimulate angiogenic growth factor production in patients with pad and cli .
a sustained - release, biodegradable corticosteroid implant injected into the eye which contains 0. 7 mg of the dexamethasone, is injected into the vitreous of the eye and gradually releases medicine over time .
therapeutic angiogenesis modalities represent a broad range of interventions that generate new blood vessel growth to promote neovascularization and tissue repair. presently, there are three major indications for which angiogenic therapies are in clinical use :
a particular area of interest and expertise of dr. beliveau is in the discovery and application of natural antiangiogenic and antitumor substances found in the diet for cancer prevention and treatment. this burgeoning area of research includes natural angiogenesis inhibitors found in green tea, cruciferous vegetables, soy, berries, and curcumin. dr. beliveau is the author of the best sellers “foods that fight cancer” and “cooking with foods that fight cancer”. he won the grand prize at the montreal book fair and was named personality of the year 2006 by l’actualité magazine and personality of québec by the au québec magazine, in 2007 .
she has contributed to a variety of medical breakthroughs, including elucidating the main mechanisms of metastatic disease and angiogenesis, identifying novel functional domains and sequences of the hiv - tat protein, and originating the concept of “angioprevention, ” amongst other unique contributions to the field of disease prevention. she developed new synthetic molecules and flavonoid derivatives for cancer prevention, and invented the most widely used in vitro invasion assay, a publication with over 1, 900 citations .
in 1990, dr. harris moved to columbus, ohio, to chair the department of preventative medicine at ohio state, and in 1995, he became the founding director of the ohio state university school of public health. dr. harris is a renowned expert on the role of cox - 2 in chronic inflammation and in promoting tumorigenesis and angiogenesis, and has authored numerous papers in peer - reviewed journals and book chapters on the use of nsaids and selective cox - 2 inhibitors in the chemoprevention of various cancer types .
professor smith is a consultant paediatric haematologist at our lady’s children’s hospital dublin, and is professor of haematology at the university of dublin, trinity college dublin. his active research areas of interest include: childhood and adolescent leukaemias & lymphomas, bone marrow failure syndromes, angiogenesis and haematological malignancies, the molecular and cellular basis of the inflammatory – coagulation interface in human disease .
dr. losordo received his m. d. from the university of vermont and completed his internship and residency at st. elizabeth’s hospital, boston. he has served on the editorial boards of a number of prestigious peer reviewed publications and has lectured widely on the potential applications of therapeutic angiogenesis in cardiovascular disease. in addition to his medical degrees, dr. losordo holds a b. a. from the university of vermont .
a fusion protein consisting of the extracellular domain 2 of vegfr1 and extracellular domains 3 and 4 of vegfr2 combined with the fc portion of the human immunoglobulin g1 .
she is a member of the board of women in development of greater boston, and served on the boards of the massachusetts chapter of the nsfre, now the afp, and the hospice at home / friends of hospice until its dissolution in 2003. quentin graduated from bryn mawr college with a degree in english literature .
through research, education, and advocacy — with patients, physicians, researchers, industry, payers, and government — we enable patients to gain access to safe and effective treatments coming from the angiogenesis field for cancer, blinding diseases, wounds, and many other serious diseases .
dr. albini has spent most of her scientific and academic career in experimental and translational oncology. her main fields of interest are angiogenesis, anti - angiogeneic gene therapy, chemoprevention, immunopathogenesis, invasion and metastasis, nanoparticles, nanotoxicology, the tumour microenvironment, and vascular biology .
a humanized monoclonal antibody that binds biologically active forms of vascular endothelial growth factor (vegf) and prevents its interaction with vegf receptors (vegfr - 1 and vegfr - 2), thereby inhibiting endothelial cell proliferation and angiogenesis .
he currently serves as medical director of the angiogenesis and wound healing center in the department of dermatology at the brigham & women’s hospital, and harvard medical school. his honors include the paul dudley white award, the mit - japan science and technology prize, first place award in the scientific and clinical poster competition at the american academy of dermatology annual meeting, and the highest recognition (daland award) from the new england cancer society. dr. li received his bachelor’s degree magna cum laude, from harvard college, his m. d. cum laude from harvard medical school and m. i. t. ’s health sciences & technology division, and his m. b. a. from harvard business school .
she has authored numerous papers in high - level peer - reviewed journals on the use of therapeutic angiogenesis and other modalities for limb preservation in patients at high risk for amputation. dr. driver previously served as director of clinical research at the center for lower extremity ambulatory research (clear) at the dr. william m scholl college of podiatric medicine, rosalind franklin university of medicine and science .
he is recognized internationally as an expert in the field of wound healing: he has 100 published papers and has given more than 200 invited lectures throughout the world. he consults for numerous wound care industrial partners in the development of new products for the wound care space. he has been a member of the board of directors of the wound healing society and recently was an author on four of the national guidelines for the treatment of chronic wounds .
in 2009 harris was elected as a fellow in the american association for the advancement of science (aaas) .
they were located on open wards as well, but those patients were the private patients of staff members, while the large first - floor pavilions were the provinces of the house staff. a three floor private service was housed near the pillared entrance of the hospital. it was scarcely lucullan in its appointments, but there the tired interns could make a decent breakfast for themselves on sunday mornings .
in 2009 he was elected vice - president of the american college of hyperbaric medicine. he also currently serves on the board for the association for the advancement of wound care. recently, dr. serena returned from haiti where he was the wound care team leader for the university of miami’s medishare hospital. he has done extensive medical relief work with health volunteers overseas and serves as chairman of the
an update from dr. william li, president of the angiogenesis foundation. since his february 2010 ted talk about fighting cancer by eating healthy, dr. li has been studying exactly which foods help most. more information at urltoken about tedx, x = independently organized event: in the spirit of ideas worth spreading, tedx is a program of local, self - organized events that bring people together to share a ted - like experience. at a tedx event, tedtalks video and live speakers combine to spark deep discussion and connection in a small group. these local, self - organized events are branded tedx, where x = independently organized ted event. the ted conference provides general guidance for the tedx program, but individual tedx events are self - organized. * (* subject to certain rules and regulations )
references: li vw, kung ef, li ww. molecular therapy for wounds: modalities for stimulating angiogenesis and granulation. manual of wound management (bok lec, editor) mcgraw hill, 2004, p. 17 - 43 .
jeffrey tarrant has more than three decades of experience picking emerging talent. prior to founding mov37 and protégé partners, jeffrey managed institutional size alternative investments for private family fortunes and was a member of the board of the investment fund for foundations. jeffrey is known for investing in and seeding emerging managers, many of whom have become renowned names in the industry. during this time, jeffrey also created altvest (now a division of morning star), the hedge fund industry’s first internet - based commercial database and analytics systems. jeffrey was founder and director of ark, (absolute return for kids), a u. k. based charity with a mission to transform the lives of children. he is currently a director of witness, a global human rights organization, and he is on the advisory board of the angiogenesis foundation. jeffrey’s philanthropic efforts include active support for many award - winning social issue documentary films. jeffrey tarrant is a graduate of harvard business school and university of california at davis .
she is an expert on the use of multi - modality approaches to wound care, including therapeutic angiogenesis, and is involved in a number of phase ii and phase iii studies of topical angiogenic growth factors and gene therapy. dr. driver is credited with the development and directorship of two major multidiscipline limb preservation centers—one for the military in washington state and one for a major teaching hospital and university in illinois .
a recombinant fusion protein that consists of vegf - binding portions from the extracellular domains of human vegf receptors 1 and 2 fused to the fc portion of the human igg1 immunoglobulin .
the co - author of more than 300 research original articles, letters, books, book chapters and papers, professor smith is a fellow of the royal college of pathologists, the royal college of physicians of dublin, london, glasgow, edinburgh and the royal college of paediatrics and child health. he is a member of numerous associations and societies, including; the medical research council childhood leukaemia working party, the international berlin frankfurt munster study group for childhood leukaemia, the united kingdom haemophilia centre directors organisation, the european paediatric network for haemophilia management, the united kingdom children’s cancer group, the paediatric haematology forum of the british society of haematology, and the european paediatric network for severe congenital neutropenia .
george w. thorn was an electric figure in medicine. at the age of 36 he burst on the scene at harvard medical school in 1942 as the ninth hersey professor of the theory and practice of physic and the third physician in chief of the department of medicine at the then peter bent brigham hospital. frequently mistaken for a medical student or resident, he remained youthful in outlook and appearance until his 90s. he died on 26 june 2004 at the age of 98 .
more veterinarians are specializing in the treatment of cancer in animals. the american college of veterinary internal medicine certified five veterinary oncologists this year, bringing the total to 122 specialists worldwide .
cindy has also utilized her success to help raise money and awareness for issues close to her heart. she’s a passionate supporter of cancer charities, having lost her brother jeff to leukemia when she was 9 years old. as part of her healing, her mother organized a dance marathon to help raise money for the leukemia foundation of america. at a young age, cindy saw how empowering it was to get involved and give back. this has inspired her devotion to help make the world a better place .
dr. douglas w. losordo is an interventional cardiologist specializing in the field of therapeutic angiogenesis for the treatment of cardiovascular - related diseases. he is director of the feinberg cardiovascular research institute and program in cardiovascular regenerative medicine at northwestern university feinberg school of medicine. dr. losordo is internationally recognized for his groundbreaking work in the use of gene, protein, and cell therapies to promote new blood vessel growth in patients with peripheral artery disease (pad) and critical limb ischemia (cli) .
molecular and cellular biologist with expertise in cancer research and tumor angiogenesis. dr. almog received a ph. d. from the weizmann institute of science, israel, where she was studying the molecular mechanisms regulating the activity of the tumor suppressor protein p53. dr. almog did her post - doctoral training in the laboratory of dr. judah folkman, at the children’s hospital and harvard medical school, boston. under folkman’s guidance, she generated and characterized in - vivo models of human tumor dormancy. she continued to develop these models and to investigate the molecular and cellular mechanisms underlying human tumor dormancy as an instructor in folkman’s lab and later as an assistant professor at the center of cancer systems biology at tufts university school of medicine, boston .
komel led the strategic development platform for smith & nephew’s biological drug portfolio where she provided scientific and strategic leadership in support of the company’s biological assets (the only biological products approved by the fda in wound care). by implementing a corporate - wide advocacy development strategy to engage the top thought leaders in wound care, komel was instrumental in adding value to the company .
dr. viswanathan trained at harvard college, university of pittsburgh school of medicine, and harvard school of public health. she also holds leadership positions in the american brachytherapy society and the american society for radiation oncology, and serves on the committees of the gynecologic cancer intergroup and the gynecologic cancer steering committee for the national cancer institute. she is on the editorial board of gynecologic oncology and brachytherapy, and is an editor of the text gynecologic radiation therapy: novel approaches to image - guidance and management .
a recombinant humanized igg1 kappa monoclonal antibody fragment that binds vascular endothelial growth factor - a (vegf - a) and cleavage products, and prevents their interaction with vegf receptors (vegfr - 1 and vegfr - 2), thereby inhibiting endothelial cell proliferation, angiogenesis, and vascular leakage in the retina and choroidal layers .
tissue engineered products approved by the fda include the bilayered skin substitute grafstkin (apligraf®) and the fibroblast dermal skin substitute dermagraft. these products contain living or cryopreserved cells on a matrix capable of secreting and releasing multiple angiogenic growth factors into the wound bed .
the author of two ground - breaking books on sustainability and business, eric has also published more than 70 articles in leading journals and publications including the harvard business review, forbes, the guardian, the wall street journal, cnn. com, and the christian science monitor. eric received his masters of business administration from the wharton school at the university of pennsylvania in strategic management. he is fluent in japanese, a baseball historian, and car enthusiast .
he received his m. d. summa cum laude and ph. d. from the university of athens medical school. he is a pioneer of the notes procedure for removal of the appendix .
he was awarded the graves medal by the royal academy of medicine and health research board in 2001 for his research into the pathobiology and novel therapeutic strategies in severe sepsis that had received international acclaim. in 2006, professor smith was awarded the st luke’s medal by the royal academy of medicine and st luke’s hospital for his work on improving outcomes in adolescent cancers with specific reference to the haematological malignancies. he was admitted to honorary fellowship of trinity college dublin (the oldest and most valued tradition of the university) in 2009 .
cd34 + endothelial progenitor cells (epc) derived from bone marrow or from peripheral blood have been found to enhance angiogenesis in ischemic tissues, increase transcutaneous oxygen, improve ankle - brachial index (abi), increase collateral vessels by angiography and improve healing of leg ulcers .
the first clinical trial for cancer patients using anti - angiogenic drugs was conducted in 1992. in the late' 90s, the popularity of anti - angiogenic drugs grew, resulting in many more clinical trials .
nicole stott is a retired nasa astronaut. over the course of her 27 - year career with nasa, she flew two spaceflight missions and spent 104 days living and working in space on both the space shuttle and the international space station (iss). stott’s many accomplishments include performing a seven - hour spacewalk and being the first person to guide the space station’s canadarm2 robotic arm for the first track and capture of a visiting cargo vehicle. stott was the last crew member to fly to and from their iss mission on a space shuttle and she was a member of the crew of the final flight of the space shuttle discovery, sts - 133. stott is also a nasa aquanaut and holds the women’s world record for saturation diving following her 18 - day mission with the neemo9 crew on the aquarius undersea habitat. she is now a full - time artist and sciart education advocate who believes that sharing the perspective she was blessed to experience through spaceflight has the power to increase our appreciation of and obligation to care for our home planet and each other .
komel’s educational background includes medical and cancer biology training at the university of texas health science center. she has also completed coursework at the pepperdine university graduate school of management and the iecs robert schumann school of business .
a sustained release corticosteroid implant which contains 0. 00023 mg of fluocinolone acetonide (fa), which is injected into the vitreous of the eye and is designed to release the medicine gradually for up to three years .
recently, a polar bear at the cleveland metroparks zoo developed an angiosarcoma, a tumor of the blood vessel, on its paw. because the tumor was aggressive, it needed to be removed surgically, and the bear was given a cocktail of anti - angiogenic drugs as a secondary measure .
today, jean - jacques devotes his spare time to helping other cancer sufferers and spreading the word about his revolutionary approach to the disease. he was the initiator of rethinking cancer 2017, a ground - breaking conference held in paris at institut gustave roussy, the leading cancer centre in europe .
dr. almog served as an associate program officer, oncology, at the adelson medical foundation, where she managed global and multi - institutional translational research programs. in addition to her expertise in tumor biology and a broad network of connections with leading scientists and clinicians in cancer research and clinical oncology, dr. almog has extensive hands - on experience with a variety of techniques ranging from the molecular level (dna, rna and proteins) to tissue, organ and mouse models in cancer biology, as well as extensive experience in project management and program coordination. dr. almog is the author of numerous scientific publications in high impact journals as well as oral and poster presentations at international conferences.
the angiogenesis foundation , is a united states 501 ( c ) ( 3 ) nonprofit organization established in 1994 for the study of angiogenesis . the founders were former students of dr. judah folkman , a pioneer of angiogenesis research . the foundation focuses on treatments in the areas of cancer , cardiology , wound healing , dermatology , and ophthalmology . the foundation developed a therapy for canine cancer , called the navy protocol . this treatment works by starving the tumor of its blood supply . in 1998 , the foundation led the establishment of angiogenic growth factor therapy as the first advanced treatment for diabetic foot ulcers . in 2004 , they helped publicly launch the first antiangiogenic therapy for cancer , bevacizumab , starting with colorectal cancer , and later broadening to breast , lung , liver , kidney , and brain cancers . 
the angiogenesis foundation, is a united states 501 (c) (3) nonprofit organization established in 1994 for the study of angiogenesis. the founders were former students of dr. judah folkman, a pioneer of angiogenesis research. the foundation focuses on treatments in the areas of cancer, cardiology, wound healing, dermatology, and ophthalmology. the foundation developed a therapy for canine cancer, called the navy protocol. this treatment works by starving the tumor of its blood supply. in 1998, the foundation led the establishment of angiogenic growth factor therapy as the first advanced treatment for diabetic foot ulcers. in 2004, they helped publicly launch the first antiangiogenic therapy for cancer, bevacizumab, starting with colorectal cancer, and later broadening to breast, lung, liver, kidney, and brain cancers.
the angiogenesis foundation, is a united states 501 (c) (3) nonprofit organization established in 1994 for the study of angiogenesis. the founders were former students of dr. judah folkman, a pioneer of angiogenesis research. the foundation focuses on treatments in the areas of cancer, cardiology, wound healing, dermatology, and ophthalmology. the foundation developed a therapy for canine cancer, called the navy protocol. this treatment works by starving the tumor of its blood supply. in 1998, the foundation led the establishment of angiogenic growth factor therapy as the first advanced treatment for diabetic foot ulcers. in 2004, they helped publicly launch the first antiangiogenic therapy for cancer, bevacizumab, starting with colorectal cancer, and later broadening to breast, lung, liver, kidney, and brain cancers.